The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: Target suppression using a biomarker

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7368-7374

  Lee, Lucy ^a   Niu, Huifeng ^b   Rueger, Ruediger ^f   Igawa, Yuriko ^g   Deutsch, Jonathan ^c   Ishii, Nobuya ^g   Mu, Song ^d   Sakamoto, Yuuichiro ^g   Busse Reid, Rachel ^h   Gimmi, Claude ^j   Goelzer, Petra ^e   De Schepper, Stefanie ^k   Yoshimura, Yashushi ^g   Barrett, Joanne ⁱ   Ishikawa, Yuji ^g   Weissgerber, Georges ^l   Peck, Richard ^a,h  

^a HOFFMANN LA ROCHE INC   (United States)

^b Discovery Oncology   (United States)

^c Drug Safety   (United States)

^d Hoffman La Roche   (United States)

^e Drug Metabolism and Pharmacokinetics   (United States)

^f ROCHE DIAGNOSTICS GMBH   (Germany)

^g CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^h Clinical Pharmacology   (Belgium)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j Pharma Research and Early Development   (Switzerland)

^k HistoGeneX NV   (Belgium)

^l Institute of Translational and Experimental Medicine   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CH 4987655; CHOLESTEROL; DRUG METABOLITE; GAMMA GLUTAMYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PLACEBO; PROTEIN KINASE INHIBITOR; RO 4987655; RO 5034027; RO 5046399; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTONOMIC DYSFUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; ELECTROCARDIOGRAM; ENZYME INHIBITION; EX VIVO STUDY; FATIGUE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STEATOSIS; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; URINARY URGENCY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PLACEBOS; TUMOR MARKERS, BIOLOGICAL;

EID: 73149086864     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1696     Document Type: Article

References (14)

1. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
2. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
3. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
5. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
6. GollobJA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406.
7. McCubrey JA, Milella M, Tafuri A, et al. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 2008;9:614-30.
8. Lee L, Niu H, Rueger R, et al. A single-ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following oral administration of a MEK inhibitor, CH4987655 (RO4987655), in healthy volunteers: implications of clinical activity using a biological marker. Abstract no. 3589. 2009.
9. Aida S, Yoshimura Y, Ishii N, et al. CH4987655 (RO4987655), a selective orally bioavailable MEK inhibitor, shows highly potent and broad antitumor activity as amonotherapy and in combination with other antitumor agents. Abstract no. 2011. 2009.
10. ChowS,HedleyD, GromP,MagariR, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry Part A 2005;67A:4-17.
11. Widakowich C, de Castro G, Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-55.
12. Yoshimura Y, Ishii N, Sakamoto H, et al. Pharmacodynamic response of CH4987655 (RO4987655), a potent and selective orally bioavailable MEK inhibitor, in preclinical models. Abstract no. 2920. 2009.
13. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:1-9.
14. Chow LQM, Eckhardt SG, Reid JM, et al. Dose-ranging study to assess the pharmacokinetics, pharmacodynamics, and toxicities of the MEK inhibitor ARRY-142886 (AZD6244) in patients with advanced solid malignancies. 2005.